{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:17:14Z","timestamp":1788419834513,"version":"build-2803163510"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01069, FI23\/00071 , MV25\/00080"],"award-info":[{"award-number":["PI22\/01069, FI23\/00071 , MV25\/00080"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by dysregulated mucosal immunity. Despite major advances in therapies, a high proportion of patients do not achieve or sustain remission. Cellular immunotherapies have emerged as a mechanistically distinct therapeutic strategy with potential relevance for refractory disease. In the present paper, the authors aim to evaluate the rationale and current evidence supporting chimeric antigen receptor (CAR)-engineered immune cells and regulatory T (Treg)-cell\u2013based therapies in IBD. Preclinical studies and early translational data support biological plausibility and feasibility of these therapies. However, available human evidence remains limited, with sparse clinical experience and short follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted according to PRISMA guidelines. Search was performed in PubMed and EMBASE databases from inception to February 2026 including terms like \u201cIBD\u201d, \u201cCAR-T\u201d, \u201cCAR-Treg\u201d and \u201cTreg therapy\u201d among others. Eligible studies included preclinical, translational and clinical reports evaluating CAR-engineered immune cells in IBD models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 11 studies met the inclusion criteria after the screening and were included in the review. CAR-Treg technologies build upon advances achieved with conventional CAR-T cells in oncology and enable antigen-specific immune regulation rather than cytotoxicity. Preclinical studies and early translational data support biological plausibility and feasibility. However, available human evidence remains limited, with sparse clinical experience and short follow-up. Major unresolved issues include cellular persistence, phenotypic stability (particularly for Tregs), optimal antigen selection, manufacturing scalability, and long-term safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cellular immunotherapies represent a promising but still investigational therapeutic paradigm in IBD. Robust clinical trials with standardized endpoints and long-term safety monitoring are needed before their clinical adoption.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1920203","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:47:20Z","timestamp":1788418040000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging CAR-Treg and regulatory T cell therapies for inflammatory bowel diseases: a systematic review of a new era of treatment"],"prefix":"10.3389","volume":"17","author":[{"given":"Fabio","family":"Suarez-Trujillo","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Medicine, BC Children\u2019s Hospital Research Institute, Division of Infectious Diseases, University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.046","article-title":"Recent insights into the genetics of inflammatory bowel disease","volume":"140","author":"Cho","year":"2011","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819847034","article-title":"EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain","volume":"12","author":"Chaparro","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.88","article-title":"Gut microbiota and IBD: causation or correlation","volume":"14","author":"Ni","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrgastro.2016.169","article-title":"The intestinal epithelial barrier: a therapeutic target","volume":"14","author":"Odenwald","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the IOIBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2014.01.002","article-title":"Biologic therapies in inflammatory bowel disease","volume":"163","author":"Cohen","year":"2014","journal-title":"Transl Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13706","article-title":"Risankizumab: mechanism of action, clinical and translational science","volume":"17","author":"Pang","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01762-8","article-title":"Ozanimod: a review in ulcerative colitis","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.dld.2023.06.009","article-title":"Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: meta-analysis","volume":"56","author":"Barberio","year":"2024","journal-title":"Dig Liver Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/gutjnl-2024-332919","article-title":"Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet","volume":"74","author":"Neurath","year":"2025","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.015","article-title":"Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier","volume":"142","author":"Esensten","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117087","article-title":"Regulatory T cells and their role in inflammatory bowel disease: molecular targets, therapeutic strategies and translational advances","volume":"239","author":"Lee","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24097797","article-title":"Enhancing regulatory T cells to treat inflammatory and autoimmune diseases","volume":"24","author":"Fiyouzi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1509956","article-title":"From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases","volume":"15","author":"Bulliard","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934343","article-title":"Regulatory CAR-T cells in autoimmune diseases: progress and current challenges","volume":"13","author":"Riet","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0015-4","article-title":"Antigen-specific therapeutic approaches for autoimmunity","volume":"37","author":"Serra","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.107","article-title":"Antigen-specific immunotherapies in rheumatic diseases","volume":"13","author":"Pozsgay","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200322919","article-title":"IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy","volume":"33","author":"Jutel","year":"2003","journal-title":"Eur J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaci.2010.05.022","article-title":"Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17\/TH1 and regulatory T cells","volume":"126","author":"Vocanson","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ni1178","article-title":"Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self","volume":"6","author":"Sakaguchi","year":"2005","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1034\/j.1600-065x.2001.1820105.x","article-title":"Type 1 T regulatory cells","volume":"182","author":"Roncarolo","year":"2001","journal-title":"Immunol Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3179","article-title":"Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells","volume":"19","author":"Gagliani","year":"2013","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4263","article-title":"The microbiota regulates type 2 immunity through ROR\u03b3t+ T cells","volume":"349","author":"Ohnmacht","year":"2015","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa9420","article-title":"Individual intestinal symbionts induce a distinct population of ROR\u03b3+ regulatory T cells","volume":"349","author":"Sefik","year":"2015","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080034","article-title":"In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells","volume":"205","author":"Lochner","year":"2008","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.08.011","article-title":"Regulatory T cells reinforce intestinal homeostasis","volume":"31","author":"Barnes","year":"2009","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i3.974","article-title":"Disrupted regulatory T cell homeostasis in inflammatory bowel diseases","volume":"22","author":"Pedros","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.immuni.2019.12.002","article-title":"Precursors for nonlymphoid-tissue treg cells reside in secondary lymphoid organs and are programmed by the transcription factor BATF","volume":"52","author":"Delacher","year":"2020","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262411944","article-title":"T regulatory cells in inflammatory bowel disease-are they major players","volume":"26","author":"Sznurkowska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1651063","article-title":"Th17\/Treg imbalance in inflammatory bowel disease: immunological mechanisms and microbiota-driven regulation","volume":"16","author":"Hu","year":"2025","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127- regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall\u2019Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-092733","article-title":"Protocol for a first-in-human feasibility study of T regulatory cells (TR004) for inflammatory bowel disease using (ex vivo) Treg expansion (TRIBUTE)","volume":"15","author":"Rodger","year":"2025","journal-title":"BMJ Open"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049208","article-title":"Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial","volume":"11","author":"Voskens","year":"2021","journal-title":"BMJ Open"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf141","article-title":"Novel autologous regulatory T-cell therapy ameliorates DSS-induced colitis in humanized mice","volume":"31","author":"Khan","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.stem.2018.01.017","article-title":"CD150high bone marrow Tregs maintain hematopoietic stem cell quiescence and immune privilege via adenosine","volume":"22","author":"Hirata","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2025.104952","article-title":"Transfer of bone marrow niche-residential regulatory T cells ameliorates experimental colitis","author":"Meng","year":"2025","journal-title":"Cell Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1038\/s41467-025-62628-7","article-title":"Regulatory T cell therapy promotes TGF-\u03b2 and IL-6-dependent pro-inflammatory Th17 cell generation by reducing IL-2","volume":"16","author":"Cheng","year":"2025","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/gutjnl-2022-327075","article-title":"Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis","volume":"72","author":"Voskens","year":"2023","journal-title":"Gut"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-306919","article-title":"Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease","volume":"65","author":"Canavan","year":"2016","journal-title":"Gut"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001192","article-title":"Characterization and expansion of autologous GMP-ready regulatory T cells for TREG-based cell therapy in patients with ulcerative colitis","volume":"23","author":"Voskens","year":"2017","journal-title":"Inflammation Bowel Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the \u03b3 or \u03b6 subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adx7845","article-title":"Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function","volume":"11","author":"Boardman","year":"2025","journal-title":"Sci Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01115-w","article-title":"The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer","volume":"23","author":"Schultz","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018604","article-title":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multi-site retrospective cohort review","volume":"10","author":"Rankin","year":"2026","journal-title":"Blood Adv"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.102028","article-title":"Outcomes of tisagenlecleucel versus allogeneic hematopoietic stem cell transplantation in relapsed or refractory large B-cell lymphoma","volume":"28","author":"Kim","year":"2025","journal-title":"Cytotherapy"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025019303","article-title":"Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM","volume":"10","author":"Kamdar","year":"2026","journal-title":"Blood Adv"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/art.70070","article-title":"Successful spontaneous pregnancies and healthy neonates after dual-target CAR-T cell therapy in systemic lupus erythematosus","volume":"78","author":"Jiang","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04191-8","article-title":"Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases","volume":"32","author":"Becilli","year":"2026","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf190","article-title":"A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy\u2014case report and literature review","volume":"64","author":"Haase","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.09.024","article-title":"Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"23","author":"Friedberg","year":"2025","journal-title":"J Thromb Haemost"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2509820","article-title":"CD19 CAR T-cell therapy for autoimmune hemolytic anemia","volume":"394","author":"Li","year":"2026","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102961","article-title":"Flagellin-specific human CAR Tregs for immune regulation in IBD","volume":"134","author":"Boardman","year":"2023","journal-title":"J Autoimmun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI20295","article-title":"Bacterial flagellin is a dominant antigen in Crohn disease","volume":"113","author":"Lodes","year":"2004","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.08.015","article-title":"Crohn's patients and healthy infants share immunodominant B cell response to commensal flagellin peptide epitopes","volume":"167","author":"Zhao","year":"2024","journal-title":"Gastroenterology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac146","article-title":"Crohn's disease patients uniquely contain inflammatory responses to flagellin in a CD4 effector memory subset","volume":"28","author":"Morgan","year":"2022","journal-title":"Inflammation Bowel Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae135","article-title":"IL23R-specific CAR Tregs for the treatment of Crohn's disease","volume":"19","author":"Cui","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2508023","article-title":"CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis","volume":"393","author":"M\u00fcller","year":"2025","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2025.107071","article-title":"B cells in inflammatory bowel disease","volume":"277","author":"Castillo","year":"2026","journal-title":"Immunol Lett"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1260266","article-title":"The yin and yang of B cells in a constant state of battle: intestinal inflammation and inflammatory bowel disease","volume":"14","author":"Zogorean","year":"2023","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.225482","article-title":"Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis","volume":"60","author":"Leiper","year":"2011","journal-title":"Gut"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:47:22Z","timestamp":1788418042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2026.1920203"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1920203","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1920203"}}